Table 2. Efficacy evaluation.
| Variables | Values |
|---|---|
| Median follow-up (months), median (IQR) | 14.3 (12.3–19.3) |
| Median duration of treatment (months), median (IQR) | 4.8 (2.0–8.8) |
| Median RFS (months) (95% CI) | 7.6 (5.7–9.5) |
| 1-year RFS rate (%) | 36.1 |
| 1-year OS rate (%) | 93.3 |
IQR, interquartile range; LCSGJ, Liver Cancer Study Group of Japan; OS, overall survival PVTT, portal vein tumor thrombosis; RFS, recurrence-free survival.